Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 4, 2010, Pages

  Eckman, John A ^a   Sterba, Patricia M ^a   Kelly, Denise ^a   Alexander, Val ^a   Liu, Mark C ^a   Bochner, Bruce S ^a   MacGlashan Jr , Donald W ^a   Saini, Sarbjit S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

basophil histamine release; basophils; cat allergy; IgE; IgE receptors; mast cells; nasal allergen challenge; omalizumab; skin prick test titration

Indexed keywords

ALLERGEN; FC EPSILON RI; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB; PLACEBO; PROSTAGLANDIN D2; UNCLASSIFIED DRUG;

ADULT; ALLERGY; ARTICLE; BASOPHIL; BLOOD SAMPLING; CAT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HISTAMINE RELEASE; HUMAN; LAVAGE; MALE; MAST CELL; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; SNEEZING; SYMPTOM;

EID: 77950296135     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.09.012     Document Type: Article

References (20)

1. MacGlashan Jr. D.W. Therapeutic efficacy of omalizumab. J Allergy Clin Immunol 123 (2009) 114-115
2. Strunk R.C., and Bloomberg G.R. Omalizumab for asthma. N Engl J Med 354 (2006) 2689-2695
3. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., et al. Humanization of an antibody directed against IgE. J Immunol 151 (1993) 2623-2632
4. Schulman E.S. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 164 (2001) S6-S11
5. MacGlashan Jr. D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., McKenzie-White J., et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158 (1997) 1438-1445
6. Saini S.S., MacGlashan Jr. D.W., Sterbinsky S.A., Togias A., Adelman D.C., Lichtenstein L.M., et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162 (1999) 5624-5630
7. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., and Saini S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 114 (2004) 527-530
8. Ong Y.E., Menzies-Gow A., Barkans J., Benyahia F., Ou T.T., Ying S., et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 116 (2005) 558-564
9. Nathan R.A., Eccles R., Howarth P.H., Steinsvag S.K., and Togias A. Objective monitoring of nasal patency and nasal physiology in rhinitis. J Allergy Clin Immunol 115 (2005) S442-S459
10. Proud D., Bailey G.S., Naclerio R.M., Reynolds C.J., Cruz A.A., Eggleston P.A., et al. Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions. J Allergy Clin Immunol 89 (1992) 1098-1110
11. Naclerio R.M., Proud D., Togias A.G., Adkinson Jr. N.F., Meyers D.A., Kagey-Sobotka A., et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 313 (1985) 65-70
12. Lin H., Boesel K.M., Griffith D.T., Prussin C., Foster B., Romero F.A., et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 113 (2004) 297-302
13. Corren J., Diaz-Sanchez D., Saxon A., Deniz Y., Reimann J., Sinclair D., et al. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. Ann Allergy Asthma Immunol 93 (2004) 243-248
14. Hanf G., Noga O., O'Connor A., and Kunkel G. Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J 23 (2004) 414-418
15. Vonakis B.M., Vasagar K., Gibbons Jr. S.P., Gober L., Sterba P.M., Chang H., et al. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 119 (2007) 441-448
16. Saini S.S., Richardson J.J., Wofsy C., Lavens-Phillips S., Bochner B.S., and Macglashan Jr. D.W. Expression and modulation of FcepsilonRIalpha and FcepsilonRIbeta in human blood basophils. J Allergy Clin Immunol 107 (2001) 832-841
17. Linder A. Symptom scores as measures of the severity of rhinitis. Clin Allergy 18 (1988) 29-37
18. Hayes E.C., Lombardo D.L., Girard Y., Maycock A.L., Rokach J., Rosenthal A.S., et al. Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay. J Immunol 131 (1983) 429-433
19. Karasuyama H., Mukai K., Tsujimura Y., and Obata K. Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol 9 (2009) 9-13
20. Noga O., Hanf G., Kunkel G., and Kleine-Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol 146 (2008) 66-70